Alumis Inc. (ALMS)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Martin Babler Ph.D.
|
President, CEO & Chairman | 1.21M | -- | 1965 |
|
Dr. David M. Goldstein Ph.D.
|
Chief Scientific Officer | 821.19k | -- | 1966 |
|
Dr. Jorn Drappa M.D., Ph.D.
|
Chief Medical Officer & Head of Research and Development | 817.06k | -- | 1965 |
|
Mr. John R. Schroer C.F.A.
|
Chief Financial Officer | -- | -- | 1965 |
|
Ms. Sanam Pangali J.D.
|
Chief Legal Officer & Corporate Secretary | -- | -- | 1984 |
|
Mr. Roy C. Hardiman J.D.
|
Chief Business & Strategy Officer | 619.84k | -- | 1960 |
|
Ms. Claire Langrish Ph.D.
|
Senior VP & Head of Immunology and Translational Science | -- | -- | -- |
|
Mr. Philip Nunn Ph.D.
|
Senior VP of Pharmacology & Project Team Leader | -- | -- | -- |
|
Mr. Mark Bradley
|
Chief Development Officer | -- | -- | 1966 |
|
Mr. Kolbot By Ph.D.
|
Senior VP & Head of Technical Operations | -- | -- | -- |
Alumis Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 237
Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 8:00 PM UTC
Alumis Inc. Earnings Date
